|
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
NCT ID : 03538314
Phase : 1
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Dr. O'Day
|
|
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
NCT ID : 04502888
Phase : 1
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
NCT ID : 04410445
Phase : 3
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)
NCT ID : 04303169
Protocol Number : MK-3475-02C
Phase : 1 and 2
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)
NCT ID : 04305054
Protocol Number : MK-3475-02B
Phase : 1 and 2
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A)
NCT ID : 04305041
Protocol Number : MK-3475-02A
Phase : 1 and 2
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer (ACUPUNCTURE)
NCT ID : 02589938
Protocol Number : WF97115
Phase : 3
Location : Burbank, CA
|
Brain Tumors & Neuroscience
|
Dr. Gordon
|
|
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43)
NCT ID : 03740165
Protocol Number : MK-7339-001
Phase : 3
Location : Burbank, CA
|
Gynecologic Oncology
|
Dr. Mena
|
|
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
NCT ID : 02947347
Protocol Number : PCYC-1141-CA
Phase : 3
Location : Burbank, CA
|
Hematology Oncology
|
Dr. Mena
|
|
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
NCT ID : 02033616
Protocol Number : CL-OVA-P01-00-US
Phase : 2
Location : Burbank, CA
|
Gynecologic Oncology
|
Dr. Mena
|
|
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT ID : 03425643
Protocol Number : MK-7339-008
Phase : 3
Location : Burbank, CA
|
Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Dr. Mena and Dr. Friedman
|
|
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
NCT ID : 03976323
Protocol Number : MK-7339-006
Phase : 3
Location : Burbank, CA
|
Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Dr. Mena
|
|
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19
NCT ID : 04338360
Location : Burbank, CA
|
COVID-19
|
Dr. Harris
|
|
Study of Efficacy and Safety of MAS825 in Patients With COVID-19 (MAS-COVID)
NCT ID : NCT04382651
Protocol Number : CMAS825F12201
Phase : 2
Location : Santa Monica, CA and Mission Hills, CA
|
COVID-19
|
Dr. O'Day and Dr. Gregson
|
|
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19
NCT ID : 04425629
Phase : 1 and 2
Location : Santa Monica, CA
|
COVID-19
|
Dr. Hammond
|
|
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
NCT ID : 04426695
Phase : 1 and 2
Location : Santa Monica, CA and Mission Hills, CA
|
COVID-19
|
Dr. Hammond and Dr. Gregson
|
|
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)
NCT ID : 04409262
Phase : 3
Location : Santa Monica, CA
|
COVID-19
|
Dr. Hammond
|
|
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
NCT ID : 04382664
Phase : 2
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT ID : 04291105
Phase : 2
Location : Santa Monica, CA
|
All Solid Tumors Brain Tumors & Neuroscience Breast Surgery and Oncology Endocrine Tumors and Disorders Gastrointestinal and Hepatobiliary Tumors Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Dr. O'Day
|
|
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
NCT ID : 04406623
Phase : 1
Location : Santa Monica, CA
|
Gynecologic Oncology
|
Dr. O'Day
|
|
Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
NCT ID : 04223856
Phase : 3
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Dr. Twardowski
|
|
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
NCT ID : 03134131
Protocol Number : ONC018
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)
NCT ID : 04186845
Phase : 3
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Dr. Twardowski and Dr. Hanelin
|
|
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
NCT ID : 03802123
Phase : 2
Location : Santa Monica, CA
|
All Solid Tumors Brain Tumors & Neuroscience Breast Surgery and Oncology Endocrine Tumors and Disorders Gastrointestinal and Hepatobiliary Tumors Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Dr. O'Day
|
|
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer
NCT ID : 04186819
Phase : 3
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Dr. Twardowski and Dr. Hanelin
|
|
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT ID : 03170960
Phase : 1 and 2
Location : Santa Monica, CA
|
All Solid Tumors Brain Tumors & Neuroscience Breast Surgery and Oncology Endocrine Tumors and Disorders Gastrointestinal and Hepatobiliary Tumors Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Dr. Twardowski
|
|
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
NCT ID : 03820986
Protocol Number : K7902-003
Phase : 3
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
NCT ID : 03237325
Protocol Number : IDR-OM-02
Phase : 3
Location : Burbank, CA
|
Brain Tumors & Neuroscience
|
Dr. Mena
|
|
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
NCT ID : 4191135
Phase : 2 and 3
Location : Santa Monica, CA
|
Breast Surgery and Oncology
|
Dr. O'Day
|
|
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)
NCT ID : 03697109
Phase : 3
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Barkhoudarian
|
|
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
NCT ID : 03822117
Phase : 2
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) (KEYLYNK-008)
NCT ID : 03976362
Protocol Number : MK-7339-008
Phase : 3
Location : Burbank, CA
|
Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Dr. Mena
|
|
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (KEYLYNK-006)
NCT ID : 03976323
Protocol Number : MK-7339-006
Phase : 3
Location : Burbank, CA
|
Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Dr. Mena
|
|
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
NCT ID : 02033616
Phase : 2
Location : Burbank, CA
|
Gynecologic Oncology
|
Dr. Friedman
|
|
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)
NCT ID : 02947347
Phase : 3
Location : Burbank, CA
|
Hematology Oncology
|
Dr. Mena
|
|
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
NCT ID : 02589938
Phase : 3
Location : Burbank, CA
|
Brain Tumors & Neuroscience
|
Dr. Mena
|
|
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
NCT ID : 01872975
Location : Burbank, CA
|
Breast Surgery and Oncology
|
Dr. Sanghani
|
|
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
NCT ID : 03345095
Phase : 3
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
Pemetrexed for the Treatment of Chordoma
NCT ID : 03955042
Phase : 1
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy
NCT ID : 03978611
Phase : 1/2a
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)
NCT ID : 03924895
Phase : 3
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Dr. Twardowski
|
|
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
NCT ID : 03924856
Phase : 3
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Dr. Twardowski
|
|
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy
NCT ID : 03898180
Protocol Number : MK-7902-011
Phase : 3
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Dr. Twardowski
|
|
Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
NCT ID : 03709888
Protocol Number : JWCI-17-0101
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer
NCT ID : 03069105
Location : Santa Monica, CA
|
Cancer Support
|
Dr. Saria
|
|
CancerLife: Patient-Driven Solution in Cancer Care
NCT ID : 03371147
Location : Santa Monica, CA
|
Cancer Support
|
Dr. Saria
|
|
Allogeneic Human Mesenchymal Stem Cells for Alzheimer’s Disease
NCT ID : 02833792
Protocol Number : STEM105-M-AD
Phase : 2
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial
NCT ID : 02873312
Protocol Number : CP-STMR-OAB-002
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Langevin
|
|
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT ID : 02847559
Protocol Number : NU 16C02
Phase : 2
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
NCT ID : 03425292
Protocol Number : JWCI-17-0801
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR)
NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : 3
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
A Phase I Study of AGEN1181, an Fe-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer
NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA
|
All Solid Tumors Brain Tumors & Neuroscience Breast Surgery and Oncology Endocrine Tumors and Disorders Gastrointestinal and Hepatobiliary Tumors Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Dr. O'Day
|
|
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2
Location : Santa Monica, CA
|
Breast Surgery and Oncology Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2
Location : Santa Monica, CA
|
All Solid Tumors Brain Tumors & Neuroscience Breast Surgery and Oncology Endocrine Tumors and Disorders Gastrointestinal and Hepatobiliary Tumors Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Dr. O'Day
|
|
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors
|
Dr. O'Day
|
|
A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03463265
Protocol Number : GBM-007
Phase : 2
Location : Santa Monica, CA
|
Brain Tumors & Neuroscience
|
Dr. Kesari
|
|
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2
Location : Santa Monica, CA
|
All Solid Tumors Brain Tumors & Neuroscience Breast Surgery and Oncology Endocrine Tumors and Disorders Gastrointestinal and Hepatobiliary Tumors Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Dr. Twardowski
|
|
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : 3
Location : Santa Monica, CA
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Dr. O'Day
|
|
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy
NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II
Location : Santa Monica, CA
|
Urology and Urologic Oncology
|
Dr. Wilson
|
